Clarification of the definition of complete response in multiple myeloma

Leukemia

Volumn 29, Issue 12, 2015, Pages 2416-2417

  Durie, B G M ^a   Miguel, J F S ^b   Blade, J ^c   Rajkumar, S V ^d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

HUMAN; MULTIPLE MYELOMA;

ANTIBODIES, MONOCLONAL; HUMANS; MULTIPLE MYELOMA;

EID: 84951569958     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.290     Document Type: Letter

References (4)

1. Durie BGM, Harousseau J-L, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
2. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma (corrigenda/erratum). Leukemia 2007; 21: 1134.
3. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691-4695.
4. McCudden P, Axel A, Slaets D, Frans S, Bald J, Schecter JM, et al. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay to distinguish malignant M-protein from therapeutic antibody. J Clin Oncol 2015; 33. (abstr 8590).